vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $70.6M, roughly 1.7× Viridian Therapeutics, Inc.\DE). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -49.0%, a 54.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 18.2%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $-84.7M).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
HIPO vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $70.6M |
| Net Profit | $6.0M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 5.6% | -56.7% |
| Net Margin | 5.0% | -49.0% |
| Revenue YoY | 18.2% | 81958.1% |
| Net Profit YoY | -86.4% | 54.9% |
| EPS (diluted) | $0.31 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.4M | — | ||
| Q3 25 | $120.6M | $70.6M | ||
| Q2 25 | $117.3M | — | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $101.9M | — | ||
| Q3 24 | $95.5M | — | ||
| Q2 24 | $89.6M | — | ||
| Q1 24 | $85.1M | — |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $-34.6M | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | $-47.7M | — | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | — | ||
| Q2 24 | $-40.5M | — | ||
| Q1 24 | $-35.7M | — |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 81.3% | -56.7% | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | -41.3% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | -5.4% | — | ||
| Q2 24 | -40.7% | — | ||
| Q1 24 | -38.7% | — |
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | -49.0% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | -43.2% | — | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | — | ||
| Q2 24 | -45.2% | — | ||
| Q1 24 | -42.0% | — |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $3.77 | — | ||
| Q2 25 | $0.05 | — | ||
| Q1 25 | $-1.91 | — | ||
| Q4 24 | $1.81 | — | ||
| Q3 24 | $-0.34 | — | ||
| Q2 24 | $-1.64 | — | ||
| Q1 24 | $-1.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $436.1M | $503.0M |
| Total Assets | $1.9B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | — | ||
| Q3 25 | $247.7M | $490.9M | ||
| Q2 25 | $198.9M | — | ||
| Q1 25 | $140.9M | — | ||
| Q4 24 | $197.6M | — | ||
| Q3 24 | $191.2M | — | ||
| Q2 24 | $175.9M | — | ||
| Q1 24 | $223.4M | — |
| Q4 25 | $436.1M | — | ||
| Q3 25 | $421.5M | $503.0M | ||
| Q2 25 | $332.5M | — | ||
| Q1 25 | $322.8M | — | ||
| Q4 24 | $362.1M | — | ||
| Q3 24 | $326.4M | — | ||
| Q2 24 | $322.6M | — | ||
| Q1 24 | $351.2M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $577.1M | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-84.6M |
| Free Cash FlowOCF − Capex | $9.1M | $-84.7M |
| FCF MarginFCF / Revenue | 7.6% | -120.1% |
| Capex IntensityCapex / Revenue | 0.1% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | — | ||
| Q3 25 | $16.9M | $-84.6M | ||
| Q2 25 | $24.7M | — | ||
| Q1 25 | $-35.6M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.8M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $17.7M | — |
| Q4 25 | $9.1M | — | ||
| Q3 25 | $16.8M | $-84.7M | ||
| Q2 25 | $24.6M | — | ||
| Q1 25 | $-35.7M | — | ||
| Q4 24 | $47.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $17.6M | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 13.9% | -120.1% | ||
| Q2 25 | 21.0% | — | ||
| Q1 25 | -32.4% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -11.9% | — | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | 0.2% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
